Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

Mae Zakhour, MD, associate fellowship program director, Gynecologic Oncology fellowship, UCLA, UCLA Health, discusses the utilization of tisotumab vedotin-tftv (Tivdak) in cervical cancer.

Tisotumab vedotin is an intriguing new antibody-drug conjugate (ADC) that recently was added to the National Comprehensive Cancer Network guidelines for the treatment of cervical cancer, Zakhour says. This ADC is expected to become a viable option for patients with recurrent metastatic cervical cancer, where not many therapeutic options are available, based on clinical trial data over the past year, Zakhour explains.

Additional research is still being conducted for the use of tisotumab vedotin for these patients, and more needs to be learned regarding its toxicities, including some of the ocular adverse effects, Zakhour adds. With appropriate management of associated toxicities, the ADC may be utilized more often in the future, Zakhour concludes.